¼¼°èÀÇ ¹é½Å ¹°·ù ½ÃÀå
Vaccine Logistics
»óǰÄÚµå : 1799074
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 269 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,215,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,647,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ¹é½Å ¹°·ù ½ÃÀåÀº 2030³â±îÁö 38¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 30¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ¹é½Å ¹°·ù ½ÃÀåÀº 2024-2030³â¿¡ CAGR 4.0%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 38¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ¿î¼Û ¼­ºñ½º´Â CAGR 3.8%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 22¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. â°í ¼­ºñ½º ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 8¾ï 2,670¸¸ ´Þ·¯, Áß±¹Àº CAGR 7.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ¹é½Å ¹°·ù ½ÃÀåÀº 2024³â¿¡ 8¾ï 2,670¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 7¾ï 7,890¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 7.3%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 1.6%¿Í 3.2%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ ¹é½Å ¹°·ù ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¹é½Å ¹°·ù°¡ ´Ù¸¥ ÄݵåüÀÎ ½ÃÀå¿¡ ºñÇØ À¯µ¶ º¹ÀâÇÑ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¹é½Å ¹°·ù´Â ÄݵåüÀÎ ¹°·ù »ê¾÷¿¡¼­ Ãʽŷڼº ¿Âµµ °ü¸®, ½Ã°£ Á¦¾àÀÌ ÀÖ´Â À¯Åë, Áö¿ª °£ ±ÔÁ¤À» ÁؼöÇÏ´Â ÃßÀû¼ºÀÌ ¿ä±¸µÇ´Â µ¶Æ¯ÇÑ Æ´»õ ½ÃÀåÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÀÏ¹Ý ÀǾàǰÀ̳ª ½Å¼±½Äǰ°ú ´Þ¸® ¹é½ÅÀº »ý¹°Á¦Á¦À̱⠶§¹®¿¡ ¿Âµµ ÀÓ°è°ªÀÌ Á¼°í(´ëºÎºÐ 2¡É-8¡É), °æ¿ì¿¡ µû¶ó¼­´Â(mRNA ¹é½Åó·³) -70¡É¿¡¼­ ³Ãµ¿ ¿î¼ÛÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Á¶°ÇÀº ù ¹øÂ° ¸¶ÀÏÀÇ Á¦Á¶, Áß°£ ¸¶ÀÏÀÇ Ç×°ø/ÇØ»ó ¿î¼Û, ¸¶Áö¸· ¸¶ÀÏÀÇ Áø·á¼Ò ¹× ¿¹¹æÁ¢Á¾ ¼¾ÅÍ·ÎÀÇ ¹è¼ÛÀ» ÅëÇØ Áö¼ÓÀûÀ¸·Î À¯ÁöµÇ¾î¾ß ÇÕ´Ï´Ù. ¾à°£ÀÇ ¿Âµµ ÀÌ»óµµ ¹é½ÅÀ» »ç¿ëÇÒ ¼ö ¾ø°Ô ¸¸µé ¼ö ÀÖÀ¸¸ç, ±× °á°ú °Ç°­ À§Çè, ±ÔÁ¤ À§¹Ý, °æÁ¦Àû ¼Õ½ÇÀÌ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19 ¹é½ÅÀÇ Ãâ½Ã·Î ¹é½Å ¹°·ùÀÇ ±Ô¸ð¿Í º¹À⼺ÀÌ µå·¯³ª¸é¼­ ÃÊÀú¿Â ³Ãµ¿°í, IoT Áö¿ø º¸¿Â Æ÷Àå, ½Ã°¢È­ ¼ÒÇÁÆ®¿þ¾î¿¡ ´ëÇÑ ÅõÀÚ°¡ ÃËÁøµÇ¾ú½À´Ï´Ù. ÆÒµ¥¹Í»Ó¸¸ ¾Æ´Ï¶ó Á¤ºÎ, À¯´Ï¼¼ÇÁ, Gavi°¡ °ü¸®ÇÏ´Â ÀÏ»óÀûÀÎ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥¿¡¼­´Â ¿¬°£ ¼ö½Ê¾ï ȸ ºÐ·®ÀÇ ¹é½ÅÀ» ¿ÀÁö¿Í ¼Ò¿ÜµÈ Áö¿ª¿¡ Àü´ÞÇØ¾ß ÇÕ´Ï´Ù. À̸¦ À§ÇØ Æ¯¼ö ´Ü¿­ Æ÷Àå(»óº¯È­¹°Áú, Áø°ø ´Ü¿­ ÆÐ³Î), ÆÐ½Ãºê Ä𸵠¹Ú½º, ¸ÖƼ¸ð´Þ ¿¬°è°¡ ÇÊ¿äÇÕ´Ï´Ù. ¶ÇÇÑ ¹Ì»ç¿ë ¶Ç´Â ¸¸·áµÈ ¿ë·®ÀÇ ¿ª¹°·ù °ü¸®, Åë°ü È¿À²È­, °¢±¹ÀÇ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥°ú ¼¼°èº¸°Ç±â±¸(WHO)¿ÍÀÇ Á¶Á¤ µîÀÌ °úÁ¦·Î ´ëµÎµÇ°í ÀÖ½À´Ï´Ù.

¹é½Å ¿î¼Û ¹× º¸°üÀÇ ¹Ì·¡¸¦ ¹Ù²Ü ±â¼úÀº ¹«¾ùÀΰ¡?

¹é½Å ¹°·ù´Â µðÁöÅÐ °ø±Þ¸Á Ç÷§Æû, ½Ç½Ã°£ »óÅ ¸ð´ÏÅ͸µ, AI¿¡ ÀÇÇÑ °æ·Î °èȹÀ¸·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. ¹é½ÅÀÇ Æ÷Àå ¹× ¿î¼Û ¿ë±â¿¡ ³»ÀåµÈ Ä¿³ØÆ¼µå ¼¾¼­ ±â¼úÀº ¿Âµµ, ½Àµµ, Áøµ¿, ºû Á¶»ç µîÀ» ½Ç½Ã°£À¸·Î ¸ð´ÏÅ͸µÇÕ´Ï´Ù. ÀÌ ¼¾¼­µéÀº ºí·çÅõ½º³ª ÈÞ´ëÆù ³×Æ®¿öÅ©¸¦ ÅëÇØ Ŭ¶ó¿ìµå ±â¹Ý ´ë½Ãº¸µå¿¡ µ¥ÀÌÅ͸¦ Àü¼ÛÇÏ¿© »çÀü ¿¹¹æÀû À§Çè °¨¼Ò¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÇöÀç ÀǾàǰ ¹°·ù ÇÁ·Î¹ÙÀÌ´õµéÀº AI ¾Ë°í¸®ÁòÀ» »ç¿ëÇÏ¿© º´¸ñÇö»óÀ» ¿¹ÃøÇϰí, ¹è¼Û ⱸ¸¦ ÃÖÀûÈ­Çϰí, ³¯¾¾¿Í ÁöÁ¤ÇÐÀû È¥¶õ¿¡ µû¶ó ¹è¼ÛÀ» ¿ìȸÇÏ´Â µî AI ¾Ë°í¸®ÁòÀ» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Çõ½ÅÀº µå·Ð ¹°·ù¿Í Àü±âÀÚµ¿Â÷(EV)¸¦ Ȱ¿ëÇÏ¿© ¿Üµý Áö¿ªÀ̳ª µµ½ÉÀÇ È¥ÀâÇÑ Áö¿ª¿¡¼­ ¶ó½ºÆ®¸¶ÀÏ ¹è¼ÛÀ» À§ÇÑ µå·Ð ¹°·ù¿Í Àü±âÀÚµ¿Â÷(EV)ÀÇ È°¿ëÀÔ´Ï´Ù. ž籤¹ßÀü º¸³Ã ¹Ú½º³ª ÈÞ´ë¿ë ¹é½Å ³ÃÀå°íµµ ºñÀü±âÈ­ Áö¿ª¿¡ µµÀԵǰí ÀÖ½À´Ï´Ù. µ¥ÀÌÅÍ ºÐ¼®À» ÅëÇØ ¿¹Ãø°ú Àç°í °èȹÀÌ °³¼±µÇ°í, Àç°í ºÎÁ·°ú ¹é½Å ³¶ºñ¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¹é½ÅÀÇ Ãâó, ¹èÄ¡ ±â·Ï, ±ÔÁ¦ °¨»ç ÃßÀûÀÇ À§º¯Á¶ ¹æÁö ÃßÀûÀ» À§ÇØ ºí·ÏüÀÎÀÇ ½Ãµµ°¡ °ËÅäµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µðÁöÅÐ ·¹À̾î´Â ƯÈ÷ ±ÔÁ¦ Á¶È­°¡ ºÎÁ·ÇÑ ±¹Á¦ ¹é½Å °Å·¡¿¡¼­ ½Å·Ú¸¦ ±¸ÃàÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.

Àü¹®È­µÈ ¹é½Å ¹°·ù¿¡ ´ëÇÑ ¼ö¿ä°¡ °¡Àå ±ÞÁõÇϰí ÀÖ´Â °÷Àº?

Ư¼ö ¹é½Å ¹°·ù¿¡ ´ëÇÑ ¼ö¿ä´Â ¼±Áø±¹°ú ½ÅÈï ½ÃÀå ¸ðµÎ¿¡¼­ ±ÞÁõÇϰí ÀÖÀ¸¸ç, ¿¹¹æÁ¢Á¾ ÀÏÁ¤ÀÇ È®´ë, ¼ºÀÎ ¹é½Å Á¢Á¾·ü, Àü¿°º´¿¡ ´ëÇÑ ´ëºñÃ¥ µîÀÌ ±× ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. °í¼Òµæ ±¹°¡¿¡¼­´Â °èÀý¼º µ¶°¨, RSV, ´ë»óÆ÷Áø, COVID-19 ºÎ½ºÅ͸¦ À§ÇÑ °­·ÂÇÑ ÄݵåüÀÎ ±¸Ãà¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â ½º¸¶Æ® â°í, ¿Âµµ °ü¸®Çü À¯Åë Çãºê, ¹é½Å Á¦Á¶¾÷ü, À¯Åë¾÷ü, °øÁߺ¸°Ç ½Ã½ºÅÛ °£ÀÇ API ÅëÇÕ¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù.

ÁßÀú¼Òµæ±¹°¡(LMICs)¿¡¼­´Â ¶ó½ºÆ®¸¶ÀÏ Á¢±Ù¼º, ÄݵåüÀÎ Àü±âÈ­, ¹Î°ü ¹°·ù ÆÄÆ®³Ê½Ê °­È­¿¡ ÁßÁ¡À» µÎ°í ÀÖ½À´Ï´Ù. COVAX, GaviÀÇ CCEOP(Cold Chain Equipment Optimization Platform), PATHÀÇ NextGen ÄݵåüÀÎ ¼Ö·ç¼Ç, ž翭 ³ÃÀå°í, µðÁöÅÐ VVM(¹é½Å ¹ÙÀÌ¾Ë ¸ð´ÏÅÍ), ÀÇ·áÁø ±³À° µî ¼¼°è º¸°Ç ±¸»óÀÌ ÀÇ·á Á¾»çÀÚ ´ë»ó ±³À° µµÀÔÀ» ÃßÁøÇϰí ÀÖ½À´Ï´Ù. »çÇ϶ó »ç¸· À̳² ¾ÆÇÁ¸®Ä«, µ¿³²¾Æ½Ã¾Æ, ¶óƾ¾Æ¸Þ¸®Ä« ±¹°¡µéµµ ±¹°¡ ¹é½Å ¹°·ù °ü¸® ½Ã½ºÅÛ(vLMIS)À» µµÀÔÇÏ¿© Åõ¿©·®À» ÃßÀûÇϰí Àç°í¸¦ °ü¸®ÇÏ¸ç º¸ÃæÀ» °èȹÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Àεµ, Áß±¹, ºê¶óÁú¿¡¼­´Â ±¹³» ¹é½Å Á¦Á¶°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ±¹³» ÄݵåüÀÎ ¿ª·® ¹× ÄÄÇöóÀ̾𽺠½Ã½ºÅÛÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ¹é½Å ¹°·ù ½ÃÀåÀ» ¹ßÀü½ÃŰ´Â ÈûÀº ¹«¾ùÀΰ¡?

¹é½Å ¹°·ù ½ÃÀåÀÇ ¼ºÀåÀº ¼¼°è ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ È®´ë, ¿Âµµ¿¡ ¹Î°¨ÇÑ »ý¹°Á¦Á¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÄݵåüÀÎ ÀÎÇÁ¶ó¿¡ ´ëÇÑ °ø°ø ¹× ¹Î°£ ÅõÀÚ Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. COVID-19´Â ÆÐ·¯´ÙÀÓÀÇ ÀüȯÀ» °¡Á®¿Ô°í, Àü ¼¼°è ¹é½Å À¯ÅëÀÇ Ãë¾à¼ºÀ» µå·¯³»¸ç º¸´Ù ź·ÂÀûÀÌ°í ¹ÎøÇϸç ÃßÀû °¡´ÉÇÑ ¹°·ù ½Ã½ºÅÛÀ» ±¸ÃàÇϱâ À§ÇÑ ³ë·ÂÀ» Ã˱¸Çß½À´Ï´Ù. °¢±¹ Á¤ºÎ´Â ÇöÀç Àü¿°º´ ´ëÀÀ Àü·«°ú °øÁߺ¸°Ç ¿¹»ê¿¡ ÄݵåüÀÎ ¹°·ù °èȹÀ» Æ÷ÇÔ½ÃÄÑ Àå±âÀûÀÎ ¼ö¿ä ¾ÈÁ¤À» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

ÀǾàǰÀÇ ±â¼ú Çõ½Åµµ ±× ¿øµ¿·Â Áß ÇϳªÀÔ´Ï´Ù. mRNA Ç÷§Æû, º¤ÅÍ ±â¹Ý ¹é½Å, »õ·Î¿î º¸Á¶Á¦ Á¦Á¦ÀÇ ¼ºÀå¿¡ µû¶ó ¹é½ÅÀÇ ¿Âµµ ¿ä°Ç°ú Ãë±Þ ¿ä°ÇÀÌ ´õ¿í º¹ÀâÇØÁö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó À°»ó, Ç×°ø, ÇØ»ó ¿î¼Û ÇüÅ¿¡¼­ ÷´Ü Æ÷Àå, ÆÐ½Ãºê ³Ã°¢ ½Ã½ºÅÛ, ¾×Ƽºê ¸®ÆÛ ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ WHOÀÇ »çÀü ÀÎÁõºÎÅÍ °¢±¹ÀÇ ÀûÁ¤ À¯Åë ±Ô¹ü(GDP)¿¡ À̸£±â±îÁö ±¹Á¦ÀûÀÎ ±ÔÁ¦ °­È­·Î ÀÎÇØ ¹°·ù ÇÁ·Î¹ÙÀÌ´õ´Â ǰÁú º¸Áõ, ¹®¼­È­ ¹× À§Çè °ü¸® °üÇàÀ» °­È­ÇØ¾ß ÇÕ´Ï´Ù.

ÀǾàǰ ¹°·ù ½ºÅ¸Æ®¾÷¿¡ ´ëÇÑ »ç¸ðÆÝµå ¹× º¥Ã³Ä³ÇÇÅ»ÀÇ ÅõÀÚ´Â ÄݵåüÀÎ ¿ª·®À» È®´ëÇÏ´Â ¼¼°è ¹°·ù ´ë±â¾÷(DHL, UPS, Kuehne+Nagel µî)°ú ÇÔ²² ½ÃÀåÀÇ °ü½ÉÀ» ´õ¿í ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ±âÈÄ º¯È­, ¼¼°è °Ç°­ À§Çù, °øÆòÇÑ ¹é½Å Á¢±Ù¿¡ ´ëÇÑ ¿ä±¸°¡ ¼¼°è º¸°Ç ȯ°æÀ» À籸¼ºÇÏ´Â °¡¿îµ¥, ½ÃÀå ȯ°æÀº µµ½Ã Á߽ɺο¡¼­ Áö¹æ ÀüÃʱâÁö, ±×¸®°í ±× »çÀÌÀÇ ¸ðµç °÷¿¡¼­ ¿¹¹æÁ¢Á¾ ¼º°ú¸¦ ´ë±Ô¸ð·Î Á¦°øÇÏ´Â µ¥ ÀÖÀ¸¸ç, ÇÙ½ÉÀûÀÎ ¿ªÇÒÀ» ÇÒ °ÍÀÔ´Ï´Ù.

ºÎ¹®

¼­ºñ½º(¿î¼Û, â°í, ºÎ°¡°¡Ä¡), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, ÀǾàǰ Á¦Á¶¾÷ü¡¤À¯Åë, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ´ë·® ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Vaccine Logistics Market to Reach US$3.8 Billion by 2030

The global market for Vaccine Logistics estimated at US$3.0 Billion in the year 2024, is expected to reach US$3.8 Billion by 2030, growing at a CAGR of 4.0% over the analysis period 2024-2030. Transportation Service, one of the segments analyzed in the report, is expected to record a 3.8% CAGR and reach US$2.2 Billion by the end of the analysis period. Growth in the Warehousing Service segment is estimated at 4.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$826.7 Million While China is Forecast to Grow at 7.3% CAGR

The Vaccine Logistics market in the U.S. is estimated at US$826.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$778.9 Million by the year 2030 trailing a CAGR of 7.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 3.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR.

Global Vaccine Logistics Market - Key Trends & Drivers Summarized

What Makes Vaccine Logistics Uniquely Complex Compared to Other Cold Chain Markets?

Vaccine logistics occupies a distinct niche within the cold chain logistics industry, demanding ultra-reliable temperature control, time-sensitive distribution, and regulatory-compliant traceability across geographies. Unlike general pharmaceuticals or perishables, vaccines are biologics with narrow thermal thresholds-often between 2°C and 8°C-and in some cases (like mRNA vaccines) requiring deep-frozen transport at -70°C. These conditions must be maintained continuously through first-mile manufacturing, mid-mile air/sea transport, and last-mile delivery to clinics or immunization centers. Even minor temperature excursions can render vaccines unusable, resulting in health risks, regulatory non-compliance, and financial losses.

COVID-19 vaccine deployment revealed the scale and complexity of vaccine logistics, driving investments in ultra-low temperature freezers, IoT-enabled thermal packaging, and visibility software. Beyond pandemics, routine immunization programs managed by governments, UNICEF, and Gavi require annual delivery of billions of doses to remote and underserved locations. This necessitates specialized packaging (phase-change materials, vacuum insulation panels), passive cooling boxes, and multi-modal coordination. Challenges also include managing reverse logistics for unused or expired doses, ensuring customs clearance efficiency, and coordinating between national immunization programs and global health agencies.

Which Technologies Are Reshaping the Future of Vaccine Transport and Storage?

Vaccine logistics is being transformed by digital supply chain platforms, real-time condition monitoring, and AI-assisted route planning. Connected sensor technologies embedded in vaccine packaging or transport containers monitor temperature, humidity, vibration, and light exposure in real time. These sensors transmit data via Bluetooth or cellular networks to cloud-based dashboards, enabling proactive risk mitigation. Pharmaceutical logistics providers now use AI algorithms to predict bottlenecks, optimize delivery windows, and reroute shipments based on weather or geopolitical disruptions.

Another innovation is the use of drone logistics and electric vehicles (EVs) for last-mile delivery in remote or urban-congested areas. Solar-powered cold boxes and portable vaccine refrigerators are also being deployed in off-grid regions. Data analytics is improving forecasting and inventory planning, reducing both stockouts and vaccine wastage. Blockchain pilots are being explored for tamper-proof tracking of vaccine provenance, batch records, and regulatory audit trails. These digital layers are essential to building trust, especially in international vaccine trade, where regulatory harmonization is often lacking.

Where Is the Demand for Specialized Vaccine Logistics Growing Most Rapidly?

Demand for specialized vaccine logistics is surging across both developed and emerging markets, driven by expanded immunization schedules, adult vaccine uptake, and epidemic preparedness initiatives. In high-income countries, the focus is on building resilient cold chains for seasonal influenza, RSV, shingles, and COVID-19 boosters. These regions are also investing in smart warehousing, temperature-controlled distribution hubs, and API integrations between vaccine manufacturers, distributors, and public health systems.

In low- and middle-income countries (LMICs), the emphasis is on last-mile access, cold chain electrification, and strengthening of public-private logistics partnerships. Global health initiatives-such as COVAX, Gavi’s Cold Chain Equipment Optimization Platform (CCEOP), and PATH’s NextGen cold chain solutions-are driving deployment of solar refrigerators, digital VVMs (vaccine vial monitors), and training for health workers. Countries in Sub-Saharan Africa, Southeast Asia, and Latin America are also adopting national vaccine logistics management systems (vLMIS) to track doses, manage inventories, and plan replenishments. Additionally, domestic vaccine manufacturing growth in India, China, and Brazil is increasing the need for intra-national cold chain capacity and compliance systems.

What Forces Are Powering the Global Vaccine Logistics Market Forward?

The growth in the vaccine logistics market is driven by several factors, including expanded global immunization programs, rising demand for temperature-sensitive biologics, and increasing public and private investment in cold chain infrastructure. COVID-19 created a paradigm shift, exposing vulnerabilities in global vaccine distribution and catalyzing efforts to build more resilient, agile, and traceable logistics systems. National governments are now incorporating cold chain logistics planning into pandemic preparedness strategies and public health budgets, ensuring long-term demand stability.

Pharmaceutical innovation is another driver. With the growth of mRNA platforms, vector-based vaccines, and novel adjuvanted formulations, the temperature and handling requirements of vaccines are becoming more complex. This is stimulating demand for advanced packaging, passive cooling systems, and active reefer technologies across land, air, and sea modes. Moreover, international regulatory tightening-from WHO prequalification to national Good Distribution Practices (GDP)-is pushing logistics providers to enhance quality assurance, documentation, and risk management practices.

Private equity and venture capital investment in pharmaceutical logistics startups, along with global logistics majors expanding cold chain capacity (e.g., DHL, UPS, Kuehne+Nagel), further reflect growing market interest. As climate change, global health threats, and demand for equitable vaccine access reshape the global health landscape, the vaccine logistics market will remain central to delivering immunization outcomes at scale-across urban centers, rural outposts, and everything in between.

SCOPE OF STUDY:

The report analyzes the Vaccine Logistics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Service (Transportation Service, Warehousing Service, Value-Added Services); End-User (Hospitals End-User, Drug Manufacturers & Distributors End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â